S-1/A: Dror Ortho-Design Files Amendment No. 1 to Form S-1 Registration Statement for Resale of Common Stock

Dror Ortho-Design, Inc. files an amendment to its S-1 registration statement to register the resale of over 2.3 billion shares of common stock by selling securityholders.

Summary

• Dror Ortho-Design, Inc. has filed Amendment No. 1 to its Form S-1 registration statement with the SEC.
• The registration statement covers the offer and sale of 2,304,316,461 shares of common stock by selling securityholders.
• These shares include 293,145,818 shares of common stock, 1,046,336,224 shares underlying Series A Convertible Preferred Stock, 474,999,993 shares underlying Private Placement Warrants, and 489,834,426 shares underlying Share Exchange Warrants.
• The company will not receive any proceeds from the sale of these shares by the selling securityholders, except to the extent that warrants are exercised for cash.
• The company intends to use any proceeds from warrant exercises for general corporate purposes.
• The selling securityholders may resell the shares through public or private transactions at a fixed price of $0.011 per share until the common stock is listed on a public trading market, and thereafter at prevailing market prices or privately negotiated prices.
• The company's common stock is currently quoted on the OTC Pink Market under the symbol DROR.
• As of April 12, 2024, the last reported sales price for the common stock was $0.005 per share.

Sentiment

Score: 5

Explanation: The document is a regulatory filing, so the sentiment is neutral. It presents facts about the company and its securities offering without expressing strong positive or negative opinions.

Positives

• The registration allows selling securityholders to potentially liquidate their holdings.
• The company may receive proceeds from warrant exercises, which will be used for general corporate purposes.

Negatives

• The company will not receive any proceeds from the sale of common stock by the selling securityholders.
• The company's common stock is currently quoted on the OTC Pink Market, which may indicate limited liquidity and investor interest.
• The last reported sales price of $0.005 per share on April 12, 2024, is significantly below the fixed resale price of $0.011 per share.

Risks

• Investment in the company's common stock involves risk, as detailed in the Risk Factors section of the prospectus.
• The company is in the development stage and is not generating revenues.
• The company faces competition from established aligner companies.
• The company's common stock is not listed on any stock exchange and there is a limited market for shares of common stock.
• The company's stock price may be volatile.

Future Outlook

The company intends to use proceeds from warrant exercises for general corporate purposes and is preparing to apply for 510(k) clearance for its Platform.

Industry Context

The company aims to disrupt the aligner market by offering a revolutionary alternative to traditional aligner solutions.

Stakeholder Impact

• Selling securityholders may benefit from the opportunity to liquidate their holdings.
• Potential investors should carefully consider the risks associated with investing in the company's common stock.
• The company may benefit from proceeds from warrant exercises, which will be used for general corporate purposes.

Next Steps

• Selling securityholders may offer or sell the shares of common stock from time to time through public or private transactions.
• The company intends to apply to have its common stock listed for trading on The Nasdaq Stock Market.

Key Dates

Keywords

common stock, registration statement, resale, selling securityholders, Series A Preferred Stock, Private Placement Warrants, Share Exchange Warrants, OTC Pink Market, DROR, Dror Ortho-Design